AGEAS

HEALTH CHECK

16/05/24 -"As we have consistently argued over the last 3 years, Health stocks (ex Pharma) are long on growth promises and short on delivery. The gap stems from the fact that delivery hinges on buying the next ..."

PDF page sample
Pages
46
Language
English
Published on
16/05/24
Download
You may also be interested by these reports :
14/08/26
Talanx reported strong 2Q26 results, particularly at the net profit level, supported by better-than-expected net financial income. Positive momentum ...
12/08/26
Hannover Re published solid 2Q26 results, slightly ahead of consensus. The FY26 net income target of above €2.7bn was reaffirmed and looks well ...
12/08/26
Sampo released a good set of Q2 26 results, showing accelerating top-line growth driven by the Private UK and Nordic Commercial segments. ...
11/08/26
NN Group has reported strong 1H26 results, with continued positive momentum in CEE driven by protection products and robust operating performance in ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO